Nolte H, et al. - Researchers undertook this current investigation to assess the effect on the safety profile of SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (12 SQ-HDM dose) when pre-specified local application site reactions were solicited vs unsolicited, and to discuss ramifications of adverse event (AE) solicitation. They observed that solicitation did not alter the safety profile as the safety profile of 12 SQ-HDM was similar when AEs were solicited vs unsolicited, qualitatively. Additionally, higher observed frequencies of local application site reactions with AE solicitation may be partly ascribed to suggestive reporting bias, as observed in placebo-treated subjects.